Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
0.800
+0.032 (4.22%)
At close: Mar 9, 2026, 4:00 PM EDT
0.801
+0.001 (0.13%)
After-hours: Mar 9, 2026, 7:56 PM EDT
Dyadic International Revenue
Dyadic International had revenue of $1.16M in the quarter ending September 30, 2025, a decrease of -40.50%. This brings the company's revenue in the last twelve months to $3.34M, down -0.66% year-over-year. In the year 2024, Dyadic International had annual revenue of $3.50M with 20.58% growth.
Revenue (ttm)
$3.34M
Revenue Growth
-0.66%
P/S Ratio
8.66
Revenue / Employee
$557,033
Employees
6
Market Cap
28.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.50M | 596.58K | 20.58% |
| Dec 31, 2023 | 2.90M | -31.50K | -1.07% |
| Dec 31, 2022 | 2.93M | 526.47K | 21.90% |
| Dec 31, 2021 | 2.40M | 801.91K | 50.06% |
| Dec 31, 2020 | 1.60M | -79.16K | -4.71% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kyntra Bio | 8.30M |
| Evaxion | 7.53M |
| Cue Biopharma | 7.10M |
| IGC Pharma | 1.11M |
| RenovoRx | 928.00K |
| Exicure | 500.00K |
DYAI News
- 5 days ago - Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free) - GlobeNewsWire
- 7 days ago - Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone - GlobeNewsWire
- 20 days ago - Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin - GlobeNewsWire
- 3 months ago - Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins - GlobeNewsWire
- 3 months ago - Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript - Seeking Alpha
- 3 months ago - Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets - GlobeNewsWire
- 4 months ago - Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress - GlobeNewsWire